Cohorts eligible for community COVID-19 treatments who require contact by consultants
Publication approval reference: C1645_ii
On 30 May 2022, the Department of Health and Social Care published an Independent Advisory Group report which identifies cohorts deemed to be at the highest risk of an adverse COVID outcome and potentially eligible for COVID-19 treatments.
This table summarises the patients who cannot be identified digitally in national datasets and are therefore requiring contact by consultants.
Patients who are digitally identified receive direct communications from NHS England with information about COVID-19 treatments and how to access them. If these patients test positive, they should be automatically contacted by a COVID-19 medicines delivery unit (CMDU) for assessment and potential treatment.
Consultants have been asked to contact all of those who are not digitally identified. Instructions and a template letter which can be adapted for patients is available on the NHS England website. These patients will need to be referred to a CMDU if they test positive as they will not show up on CMDU systems automatically.
For the full eligibility criteria, including specific criteria related to clinical conditions in this table, please refer to the clinical commissioning policy and Independent Advisory Group report.
More information on the digital pathway and methodology is available on the NHS Digital website.
|Cohort||Patients requiring contact by consultants  |
|Down’s syndrome and other genetic disorders||
|Haematological diseases and recipients of haematological stem cell transplant (HSCT)||
‒ in molecular response, or
‒ receiving tyrosine kinase inhibitors, or
‒ in the first 6 months of chemotherapy
|Solid organ transplant recipients||
|Immune-mediated inflammatory disorders||People with an autoimmune or inflammatory condition who have:
Immunosuppressive medication (if the treatment is only prescribed by their hospital)
People with an autoimmune or inflammatory condition who are on the following treatments:
People with an autoimmune or inflammatory condition who are on the following treatments (prescribed by the hospital only):
People with an autoimmune or inflammatory condition who are on methotrexate (for interstitial lung disease ONLY)
|Immune deficiencies||People with:
|Rare neurological and severe complex life-limiting neurodisability conditions||
‒ multiple sclerosis
‒ motor neurone disease
‒ myasthenia gravis
‒ Huntington’s disease
 Consultants may have already written to some of these patients. Those patients do not need to be contacted again.
 Some patients listed here may also be digitally identified and contacted directly by NHS England. However, due to various time lags with datasets being updated, we are asking consultants to write to all those listed in this table to help ensure all patients receive the information they need.